On June 24, 2022, the National Medical Products Administration (NMPA) issued the Notice on Further Strengthening Services for Foreign-funded Enterprises (hereinafter referred to as “the Notice”). Measures listed within this document pertain to and work to the benefit of entity or license holders of pharmaceuticals, medical devices and cosmetics.

The Notice clearly stated that it aims at stabilizing social and economic development, as well as specifies several measures and requirements for regional and relevant subordinate units as follows:

·   Optimize current methods to help enterprises with the registration and filing procedures for all sectors mentioned above.

·   Innovate current monitor measures, especially in the Greater Bay area (Hong Kong-Macau-Guangdong area).

·   Accelerate the review and assessment process for more urgently needed products.